KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EBITDA (2016 - 2025)

Biogen has reported EBITDA over the past 17 years, most recently at -$551.5 million for Q4 2025.

  • Quarterly results put EBITDA at -$551.5 million for Q4 2025, down 88.87% from a year ago — trailing twelve months through Dec 2025 was -$847.7 million (down 109.62% YoY), and the annual figure for FY2025 was -$847.7 million, down 109.62%.
  • EBITDA for Q4 2025 was -$551.5 million at Biogen, down from -$117.1 million in the prior quarter.
  • Over the last five years, EBITDA for BIIB hit a ceiling of $973.9 million in Q1 2021 and a floor of -$800.8 million in Q3 2023.
  • Median EBITDA over the past 5 years was $133.3 million (2023), compared with a mean of $177.2 million.
  • Biggest five-year swings in EBITDA: skyrocketed 277.59% in 2021 and later crashed 328.84% in 2024.
  • Biogen's EBITDA stood at $587.1 million in 2021, then dropped by 25.09% to $439.8 million in 2022, then tumbled by 70.99% to $127.6 million in 2023, then crashed by 328.84% to -$292.0 million in 2024, then plummeted by 88.87% to -$551.5 million in 2025.
  • The last three reported values for EBITDA were -$551.5 million (Q4 2025), -$117.1 million (Q3 2025), and $139.0 million (Q2 2025) per Business Quant data.